Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining the Pharmacokinetic Effects of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With ADHD

NCT01907360 is registered in ClinicalTrials.gov with Ironshore Pharmaceuticals and Development, Inc as lead sponsor.

NCT NCT01907360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01907360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining the Pharmacokinetic Effects of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With ADHD
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2013
Completion date
October 31, 2013
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit hyperactivity disorder